Stakeholder Consultation on Naming of Biologic Drugs

January 18 to February 9, 2018

On January 18, 2018, the Institute for Safe Medication Practices Canada (ISMP Canada) will post an online questionnaire to seek input from healthcare providers, consumers, and other interested and affected stakeholders on different approaches to the naming of biologic drugs, including biosimilars, in Canada. The questionnaire is being developed collaboratively with Health Canada. Administration of the questionnaire and analysis of responses will be performed by ISMP Canada. The objective of the consultation is to gain insight into stakeholder views on the practical impacts of different approaches to the naming of biologic drugs and biosimilars throughout the medication-use process, including prescribing, dispensing, and adverse drug reaction reporting.

Results of the consultation will be used to:
• understand the impact of different approaches to biologic drug naming and the perspectives of healthcare providers, consumers, and other interested and affected stakeholders, and
• inform Health Canada’s policy decision on a naming convention for biologic drugs.

For more details on this initiative, click here.
Additional details will also be available when the questionnaire is launched on January 18, 2018.
We would appreciate your help to distribute this message to your colleagues, members, or stakeholders to inform them of this initiative and the upcoming consultation.
If you have any preliminary questions, please contact us via info@ismp-canada.org